Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX008 in BCG-Unresponsive Non-muscle Invasive Bladder Cancer
NCT04738630Phase 2Unknown
- Sponsor
- Taizhou Hanzhong Pharmaceuticals
- Start
- Sep 2020
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pucotenlimab in bladder cancer, sponsored by Taizhou Hanzhong Pharmaceuticals. Status: unknown.
02
Drugs
pucotenlimab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT04738630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04738630.